AYAT RASSAS: Open Payments
NPI 1982446266 · GOODYEAR, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$736 in 38 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $246 · 2025 $736
Food & beverage: $736
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 8 | $205 |
| AstraZeneca Pharmaceuticals LP | 6 | $95 |
| PFIZER INC. | 4 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $64 |
| Merck Sharp & Dohme LLC | 3 | $58 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $45 |
| Lilly USA, LLC | 3 | $43 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| Seqirus USA Inc | 1 | $25 |
| Corcept Therapeutics | 1 | $25 |
Products named: Veozah, AIRSUPRA, Kerendia, ELIQUIS, XIFAXAN, ROTATEQ, TRELEGY ELLIPTA, Flucelvax.
Industry payments across AZ — which companies pay providers there.
